Prevalence and Clinical Impact of Iron Deficiency in Patients With Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation.

Rheude, Tobias; Pellegrini, Costanza; Lessmann, Leonie; Wiebe, Jens; Mayr, N Patrick; Michel, Jonathan; Trenkwalder, Teresa; Kasel, Albert M; Schunkert, Heribert; Kastrati, Adnan; Joner, Michael; Husser, Oliver; Hengstenberg, Christian

doi:10.1016/j.amjcard.2019.07.051

journal article

Titel:: Prevalence and Clinical Impact of Iron Deficiency in Patients With Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation.
Dokumenttyp:: Article; Journal Article
Autor(en):: Rheude, Tobias; Pellegrini, Costanza; Lessmann, Leonie; Wiebe, Jens; Mayr, N Patrick; Michel, Jonathan; Trenkwalder, Teresa; Kasel, Albert M; Schunkert, Heribert; Kastrati, Adnan; Joner, Michael; Husser, Oliver; Hengstenberg, Christian
Abstract:: Patients referred for transcatheter aortic valve implantation (TAVI) are typically elderly with several co-morbidities, which might limit prognosis despite successful procedural outcome. To date, the prevalence and clinical impact of iron deficiency (ID) in patients with severe aortic stenosis who underwent TAVI remains poorly defined. This study included 495 patients who underwent transfemoral TAVI for severe symptomatic aortic stenosis. ID was defined as ferritin <100 ng/ml or ferritin 100 to 300 ng/ml, when transferrin saturation was <20%. The primary end point of the study was a composite of all-cause mortality, unplanned readmission for worsening heart failure or red blood cell transfusions during the first year after TAVI, which occurred in 22% (109 of 495) of the population. ID was present in 54% (268 of 495) of the entire cohort and was associated with a higher rate of the primary end point (27.6% [74 of 268] vs 15.4% [35 of 227]; p = 0.001). After multivariable adjustment, the association of ID with the primary end point remained significant (hazard ratio 1.64, 95% confidence interval [1.08 to 2.48]; p = 0.019). In a subgroup of ferropenic patients (n = 56), treatment with intravenous iron before TAVI was feasible, resulting in a considerable improvement of ferritin, transferrin saturation and symptoms at 30-day follow-up. In conclusion, ID is common in TAVI patients and is associated with adverse clinical outcome after TAVI. Correction of ID with intravenous iron seems feasible in contemporary TAVI patients. Whether this reduces transfusion rates and impacts clinical outcome after TAVI remains to be investigated in future prospective trials.
Zeitschriftentitel:: Am J Cardiol
Jahr:: 2019
Band / Volume:: 124
Heft / Issue:: 9
Seitenangaben Beitrag:: 1442-1448
Volltext / DOI:: doi:10.1016/j.amjcard.2019.07.051
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/31474326
Print-ISSN:: 0002-9149
TUM Einrichtung:: Fachgebiet Kardioanästhesie (Prof. Tassani-Prell); Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (Prof. Schunkert)
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Lehr- und Forschungskooperationen mit den Kliniken und Instituten am Deutschen Herzzentrum Institut für Anästhesiologie (DHM) (Prof. Tassani-Prell)Professur für Kardioanästhesie (Prof. Tassani-Prell)2019

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Lehr- und Forschungskooperationen mit den Kliniken und Instituten am Deutschen Herzzentrum Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (DHM) (Prof. Schunkert)2019